Skip to main content

Table 2 Medications of RA patients before the specimens were obtained

From: (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway

Drugs The number of cases
No treatment 1
Taking non-steroidal anti-inflammatory drugs 28
Taking 1 disease modifying antirheumatic drug 4
Taking 2 disease modifying antirheumatic drug 17
Taking ≥ 3 disease modifying antirheumatic drug 4
Taking glucocorticoid 13
Taking biologics 3
  1. Disease modifying antirheumatic drugs include methotrexate, leflunomide, sulfasalazine, penicillamine, hydroxychloroquine, and some herb extracts such as total glucosides of paeony, tripterygium glycosides and the extract of Caulis Sinomenii. Dose of glucocorticoid equals to prednisone 2–10 mg daily. Biologics include Etanercept (2 cases) and Infliximab (1 case).